Literature DB >> 22960640

Targeting mitochondrial oxidative metabolism as an approach to treat heart failure.

Natasha Fillmore1, Gary D Lopaschuk.   

Abstract

Heart failure is a major cause of morbidity and mortality in the world. Cardiac energy metabolism, specifically fatty acid and glucose metabolism, is altered in heart failure and has been implicated as a contributing factor in the impaired heart function observed in heart failure patients. There is emerging evidence demonstrating that correcting these changes in energy metabolism by modulating mitochondrial oxidative metabolism may be an effective treatment for heart failure. Promising strategies include the downregulation of fatty acid oxidation and an increased coupling of glycolysis to glucose oxidation. Carnitine palmitoyl transferase I (CPT1), fatty acid β-oxidation enzymes, and pyruvate dehydrogenase kinase (PDK) are examples of metabolic targets for the treatment of heart failure. While targeting mitochondrial oxidative metabolism is a promising strategy to treat heart failure, further studies are needed to confirm the potential beneficial effect of modulating these metabolic targets as an approach to treating heart failure. This article is part of a Special Issue entitled: Cardiomyocyte Biology: Cardiac Pathways of Differentiation, Metabolism and Contraction.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960640     DOI: 10.1016/j.bbamcr.2012.08.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  46 in total

Review 1.  Heart failure and loss of metabolic control.

Authors:  Zhao V Wang; Dan L Li; Joseph A Hill
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

Review 2.  First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.

Authors:  Hazel H Szeto
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  Mitochondria as a target of cardioprotection in models of preconditioning.

Authors:  Magdaléna Jašová; Ivana Kancirová; Iveta Waczulíková; Miroslav Ferko
Journal:  J Bioenerg Biomembr       Date:  2017-07-20       Impact factor: 2.945

4.  Regulation of substrate utilization by the mitochondrial pyruvate carrier.

Authors:  Nathaniel M Vacanti; Ajit S Divakaruni; Courtney R Green; Seth J Parker; Robert R Henry; Theodore P Ciaraldi; Anne N Murphy; Christian M Metallo
Journal:  Mol Cell       Date:  2014-10-30       Impact factor: 17.970

Review 5.  MicroRNAs 33, 122, and 208: a potential novel targets in the treatment of obesity, diabetes, and heart-related diseases.

Authors:  Osama Abo Alrob; Said Khatib; Saleh A Naser
Journal:  J Physiol Biochem       Date:  2016-12-14       Impact factor: 4.158

6.  p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities.

Authors:  Jie Li; Ping-Yuan Wang; Nathaniel A Long; Jie Zhuang; Danielle A Springer; Jizhong Zou; Yongshun Lin; Christopher K E Bleck; Ji-Hoon Park; Ju-Gyeong Kang; Paul M Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-05       Impact factor: 11.205

7.  Metabolic Therapy in Heart Failure.

Authors:  Yury Lopatin
Journal:  Card Fail Rev       Date:  2015-10

8.  Metabolic remodeling of substrate utilization during heart failure progression.

Authors:  Liang Chen; Jiangping Song; Shengshou Hu
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 9.  Regulation of pyruvate metabolism in metabolic-related diseases.

Authors:  Nam Ho Jeoung; Chris R Harris; Robert A Harris
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

10.  Increased Pyruvate Dehydrogenase Kinase 4 Expression in Lung Pericytes Is Associated with Reduced Endothelial-Pericyte Interactions and Small Vessel Loss in Pulmonary Arterial Hypertension.

Authors:  Ke Yuan; Ning-Yi Shao; Jan K Hennigs; Marielle Discipulo; Mark E Orcholski; Elya Shamskhou; Alice Richter; Xinqian Hu; Joseph C Wu; Vinicio A de Jesus Perez
Journal:  Am J Pathol       Date:  2016-07-25       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.